Bipolar disorder

Brain & Behavior Research Foundation Awards Distinguished Investigator Grants Valued at $1 Million to 10 Scientists Pursuing Innovative Mental Health Research

Retrieved on: 
Thursday, April 4, 2024
Depression, Patient, Mitochondrion, Doctor of Science, Harvard University, Therapy, Research, Risk, Mental health, University of Pittsburgh, Brain, DSM-IV codes, Brown University, Cannabis, Memory, Safety, Spectrum, Mitophagy, Schizophrenia, Hippocampus, Bipolar disorder, Anxiety, Learning, University, Psychopathology, Cerebrospinal fluid, University of California, Distinguishing, PET, Biomarker, Hope, Baylor College of Medicine, Behavior, AMPA, Fragile X syndrome, PTSD, Pharmaceutical industry

New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.

Key Points: 
  • New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.
  • By funding transformative research focused on new ways to prevent, diagnose, and treat psychiatric disorders, our Distinguished Investigator Grants are encouraging established scientists to continue advancing our understanding of mental illness and disorders of brain and behavior,” says Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation.
  • The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness.
  • We applaud these scientists for their extraordinary dedication, innovation, and leadership.”
    Recipients of the Distinguished Investigator Grants are full professors at research institutions in the United States and abroad.

Tetricus Labs Partners with Silver Hill Hospital on Research to Advance Precision Psychiatry

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, Neurology, Mental Health, Research, Software, Artificial Intelligence, Hospitals, Science, Dow, Panic disorder, Psychiatry, Data science, Associate, Silver, Partnership, Patient, Tetricus, Bipolar disorder, Radiology, Neuroscience, Doctor of Philosophy, DSM-IV codes, Evercore, MD, Psychology, Silver Hill Hospital, Social anxiety disorder, Machine learning, Medical director, Yale University, Medicine, Nursing

Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.

Key Points: 
  • Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.
  • “We're patient-founded, patient-owned, and patient-run,” said Dow, CEO for Tetricus Labs.
  • Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, will join Tetricus Labs as a Medical Advisor to ensure Tetricus’ machine learning software is designed to fit within the busy workflow of hospital clinicians and staff, maximizing its accessibility for providers and potential impact on patient outcomes.
  • “This partnership represents our continued commitment to exploring innovative methods that can enhance our understanding of psychiatric disorders and improve patient outcomes."

Cathy Nguyen Named Provider of the Month at Relief Mental Health in Chicago

Retrieved on: 
Tuesday, April 2, 2024
Men, Research, General Health, LGBTQ+, Pharmaceutical, Consumer, Mental Health, Science, Neurology, Biotechnology, Women, Seniors, Health, Depression, Mental health, Brain, MDD, Empathy, Patient, Transcranial magnetic stimulation, TMS, Bipolar disorder, Anxiety, OCD, Cathy, Month, DSM-IV codes, Provider, MSN, TRD, Suicidal ideation, Field line, Esketamine, FDA, Nursing

Relief Mental Health , a leading outpatient provider of transcranial magnetic stimulation (TMS), psychedelic therapy, psychiatric medication management, and talk therapy, is thrilled to announce Psychiatric Nurse Practitioner Cathy Nguyen, MSN APRN PMHNP-BC as its esteemed Provider of the Month.

Key Points: 
  • Relief Mental Health , a leading outpatient provider of transcranial magnetic stimulation (TMS), psychedelic therapy, psychiatric medication management, and talk therapy, is thrilled to announce Psychiatric Nurse Practitioner Cathy Nguyen, MSN APRN PMHNP-BC as its esteemed Provider of the Month.
  • Nguyen has exhibited exceptional dedication and expertise in providing innovative mental health care to the community at Relief’s West Loop clinic in Chicago.
  • Susan Mueller, CEO of Relief Mental Health, expressed her admiration for Nguyen’s commitment to the organization’s core values.
  • To make an appointment with Nguyen or for more information about the innovative services offered at Relief Mental Health, call 855.205.4764, email [email protected] or visit reliefmh.com .

Minneapolis Psychiatry Clinic Adds Vagus Nerve Stimulation as Non-Drug Therapy for Severe Depression

Retrieved on: 
Wednesday, March 20, 2024
Mental Health, Surgery, Medical Devices, Alternative Medicine, Health, Vagus nerve, Deep brain stimulation, Depression, DSM-IV codes, Brain, VNS, LivaNova, Vagus nerve stimulation, Patient, TMS, Mental health, Bipolar disorder, Skin, Ketamine, Transcranial magnetic stimulation, Medicare, FDA, CMS

Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.

Key Points: 
  • Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.
  • VNS has a 70% success rate when used for treatment resistant depression, meaning the patient hasn’t responded to traditional antidepressants.
  • VNS stimulates the vagus nerve, triggering its natural process of sending electrical pulses to the parts of the brain that control mood.
  • For more information about Vagus Nerve Stimulation and what to expect, visit Advanced Brain and Body Clinic’s VNS page .

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Retrieved on: 
Friday, March 15, 2024
Science, Other Science, Biotechnology, Pharmaceutical, Oncology, Health, Mental Health, Genetics, Diagnosis, Depression, Gene, Schizophrenia, Post-traumatic stress disorder, Patient, Research, Bipolar disorder, Anxiety, Personality disorder, Polypharmacy, Pain, Geriatric psychiatry, Annual general meeting, Pharmaceutical industry

The data will be shared via a poster presentation at the 2024 American Association for Geriatric Psychiatry (AAGP) Annual Meeting, taking place March 15-18 in Atlanta.

Key Points: 
  • The data will be shared via a poster presentation at the 2024 American Association for Geriatric Psychiatry (AAGP) Annual Meeting, taking place March 15-18 in Atlanta.
  • “This study found that, despite all patients carrying potentially clinically significant genetic variants, one-third of medication recommendations were due to drug-drug interactions and lifestyle factors provided on the IDgenetix report.
  • Additionally, 58% of the patients in the study were on five or more medications, with an average of seven, at the time of testing.
  • All patients in the study had genetic polymorphisms that could impact medication selection in at least three of the 15 genes on the IDgenetix report.

The9 Signed a Definitive Share Purchase Agreement to Invest in GenAI LLM Digital Precision Medicine Platform for Brain Disease WM Therapeutic

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Depression, Sleep, The9, Synthetic media, Annual report, Myenteric plexus, Agreement, Disease, Alzheimer's disease, Central nervous system, Attention deficit, Bipolar disorder, Anxiety, AI, IPO, Insurance, Sympathetic nervous system, LLM, Drug development, WM, Spectrum, Good, Generative, Pharmaceutical industry

SHANGHAI, March 26, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares.

Key Points: 
  • SHANGHAI, March 26, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares.
  • With the signing of this Agreement, The9 will own 30% of WM Therapeutic.
  • The9 is also granted a purchase option to purchase up to 51% of the total shares of WM Therapeutic under certain conditions.
  • WM Therapeutic develops GenAI large language model brain disease screening platform and digital human personalized psychological consultant, AI precision diagnostic equipment, personalized neuromodulation treatment equipment, Generative AI large language model and AI drug clinical research platform.

CooperRiis Healing Community Introduces Direct Admission into Transitional Living Program

Retrieved on: 
Monday, March 18, 2024
Personality, Depression, Schizophrenia, Learning, Environment, Mental health, Bipolar disorder, Helsinki University Central Hospital, Partial hospitalization, Anxiety, Schizoaffective disorder, Transition, PTSD, Nursing

ASHEVILLE, N.C., March 18, 2024 /PRNewswire-PRWeb/ -- CooperRiis Healing Community, a leading mental health non-profit organization dedicated to providing compassionate and holistic care, is thrilled to announce the launch of Direct Admissions into their Transitional Living Program. This new offering expands their integrated system of care, furthering their commitment to supporting individuals on their journey to mental wellness bypassing the need to begin treatment at their residential level of care.

Key Points: 
  • CooperRiis Healing Community, a leading mental health non-profit organization dedicated to providing compassionate and holistic care, is thrilled to announce the launch of Direct Admissions into their Transitional Living Program.
  • ASHEVILLE, N.C., March 18, 2024 /PRNewswire-PRWeb/ -- CooperRiis Healing Community, a leading mental health non-profit organization dedicated to providing compassionate and holistic care, is thrilled to announce the launch of Direct Admissions into their Transitional Living Program.
  • We are excited to introduce direct admission into our Transitional Living Program.
  • Individuals interested in learning more about the Transitional Living Program and the admissions process at CooperRiis Healing Community are encouraged to visit the organization's website or contact admissions directly.

BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute

Retrieved on: 
Friday, March 8, 2024
Artificial intelligence, Bipolar disorder, Schizophrenia, LIBD, Synthetic control method, DSM-IV codes, Machine learning, Bullfrog, Partnership

GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat.

Key Points: 
  • GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat.
  • This enlightening session, hosted by RedChip Companies on March 5, 2024, featured BullFrog AI's CEO, Vin Singh, alongside Daniel R. Weinberger M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD).
  • The recording can be accessed via the following link: https://youtu.be/40rogXtHBJ8
    The fireside chat provided a deep dive into the early findings from the collaboration between BullFrog AI and LIBD.
  • This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential biological subtypes within individual disorders.

Voya Financial expands its workplace benefits offerings with new supplemental health insurance solution

Retrieved on: 
Wednesday, February 21, 2024
Technology, Professional Services, Health, Health Technology, Health Insurance, Asset Management, Apps, Applications, Software, Insurance, Human Resources, Finance, Diabetes, Anxiety, Emergency, Mental health, Workplace, Voya Financial, Bipolar disorder, Concussion, Asthma, ICD-10, Stroke, Family, DSM-IV codes, Epilepsy, International Classification of Diseases, Knowledge Organization (journal), Ageing, Research, Protection, Health insurance

Voya Financial, Inc. (NYSE: VOYA), announced today that it continues to enhance its growing portfolio of workplace benefits by offering an innovative, technology-enabled solution to help employees ease the burden of out-of-pocket medical costs.

Key Points: 
  • Voya Financial, Inc. (NYSE: VOYA), announced today that it continues to enhance its growing portfolio of workplace benefits by offering an innovative, technology-enabled solution to help employees ease the burden of out-of-pocket medical costs.
  • Voya Protect, a new Group Limited Benefit Insurance powered by the insurance technology company Ansel Health, is a supplemental health offering that is designed to pay benefits quickly and easily when covered conditions are diagnosed.
  • And, while many employers have made changes to their benefit lineups to help support their employees, the reality is that workplace benefits are complex,” explained Nate Black, vice president, Health Solutions Product at Voya Financial.
  • Voya Protect is the latest example of how Voya is focused on providing innovative solutions and capabilities to help employers and their employees optimize their workplace benefits and savings needs.

Fierce Healthcare Names Talkiatry a "Fierce 15" Company of 2024

Retrieved on: 
Tuesday, February 20, 2024
Anxiety, Adolescence, Bipolar disorder, Cigna, Health care, Medicare, Creativity, Patient, PTSD, Insurance, Child, ADHD, OCD, Face, Depression

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatric care, announced today that Fierce Healthcare has named it one of 2024's "Fierce 15" healthcare companies. The annual special report features the most innovative private healthcare companies looking to change the face of the industry. 

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatric care, announced today that Fierce Healthcare has named it one of 2024's "Fierce 15" healthcare companies.
  • The annual special report features the most innovative private healthcare companies looking to change the face of the industry.
  • "It's an honor to be featured in the 'Fierce 15' list with so many other visionary healthcare leaders," said Robert Krayn, co-founder and CEO, Talkiatry.
  • "For the past six years, we have assessed hundreds of private companies for inclusion in the 'Fierce 15' special report.